Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.

Autor: Frigault MJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA., Graham CE; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA., Berger TR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Ritchey J; Department of Medicine, Washington University School of Medicine, St. Louis, MO., Horick NK; Department of Biostatistics, Massachusetts General Hospital and Harvard Medical School, Boston, MA., El-Jawahri A; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA., Scarfò I; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA., Schmidts A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA., Haradhvala NJ; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA., Wehrli M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA., Lee WH; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Parker AL; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Wiggin HR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Bouffard A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Dey A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA., Katsis K; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Elder EL; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Dolaher MA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Cook DT; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Chekmasova AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Huang L; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Nikiforow S; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA.; Connell and O'Reilly Families Cell Manipulation Core Facility, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Daley H; Connell and O'Reilly Families Cell Manipulation Core Facility, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Ritz J; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA.; Connell and O'Reilly Families Cell Manipulation Core Facility, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Armant M; TransLab, Boston Children's Hospital, Boston, MA., Preffer F; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA., DiPersio JF; Department of Medicine, Washington University School of Medicine, St. Louis, MO., Nardi V; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA., Chen YB; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA., Gallagher KME; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA., Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA.; Department of Pathology and Department of Medicine, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.

Publikováno v: Blood [Blood] 2024 Sep 12; Vol. 144 (11), pp. 1153-1167.

Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.

Autor: Graham CE; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA., Lee WH; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Wiggin HR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Supper VM; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA., Birocchi F; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA., Yee AJ; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA.; Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA., Petrichenko A; Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA., Everett J; Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA., Bushman FD; Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA., Sadrzadeh H; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA., Rapalino O; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA.; Department of Radiology, Massachusetts General Hospital, Boston, MA., Chiu D; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA.; Department of Neurology, Massachusetts General Hospital, Boston, MA., Arrillaga-Romany I; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA.; Department of Neurology, Massachusetts General Hospital, Boston, MA., Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA., Frigault MJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA., Gallagher KME; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA.

Publikováno v: Blood [Blood] 2023 Oct 05; Vol. 142 (14), pp. 1248-1252.